United States securities and exchange commission logo





                             November 11, 2022

       Lynn Kirkpatrick
       President, Chief Executive Officer & Director
       Ensysce Biosciences, Inc.
       7946 Ivanhoe Avenue, Suite 201
       La Jolla, CA 92037

                                                        Re: Ensysce
Biosciences, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed October 28,
2022
                                                            File No. 333-268038

       Dear Lynn Kirkpatrick:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1

       General

   1.                                                   Please revise your
cover page to disclose the volume of securities you are offering on a
                                                        best-efforts basis as
required by Item 501(b)(2) of Regulation S-K. Also, please revise to
                                                        remove any disclosures
suggesting that the volume of securities has not been established.
                                                        In this regard, please
remove the following disclosure from the cover page: "All share,
                                                        warrant, and pre-funded
warrant numbers are based on an assumed combined public
                                                        offering price of $___
per share and accompanying warrants." For additional guidance,
                                                        refer to Securities Act
Rules Compliance and Disclosure Interpretations Question 227.02.
   2.                                                   Given that this is a
best-efforts, no minimum offering in which your placement agent is
                                                        not required to arrange
for the purchase and sale of any specific number or dollar amount
                                                        of shares and that you
may not sell the entire amount of common stock and warrants being
 Lynn Kirkpatrick
Ensysce Biosciences, Inc.
November 11, 2022
Page 2
         offered, please delete references on the cover page and elsewhere to
the total dollar
         amount of proceeds ($12.5 million).
3.       We note that your placement agent, Lake Street, will sell the
securities on a "best efforts"
         basis. Please revise to state on the cover page, and elsewhere as
appropriate, the date the
         offering will end. Refer to Regulation S-K, Item 501(b)(8)(iii).
4.       We note your disclosure that you expect to deliver your shares,
pre-funded warrants, and
         warrants to investors on or about an as yet to be determined date in
2022. Given that this
         is language typically included in a firm commitment underwritten
offering and you have
         indicated this is a best efforts offering, please advise us of the
reason for this disclosure.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Alan Campbell at (202) 551-4224 or Joe McCann at (202)
551-6262 with
any questions.



FirstName LastNameLynn Kirkpatrick                               Sincerely,
Comapany NameEnsysce Biosciences, Inc.
                                                                 Division of
Corporation Finance
November 11, 2022 Page 2                                         Office of Life
Sciences
FirstName LastName